DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
New biomarkers of inflammation associated with haemodialysis
Device trade names
Table contains details of the trade names associated with this document
Tradename Country Manufacturer
Phylther HF22SD Italy Bellco
Fx80 (dialyzer) Germany Fresenius Medical Care, Chemicals and CAS Registry Numbers
indican 1336-79-4, 487-94-5, Background The first year of haemodialysis (HD) carries the highest risk of mortality, which to a large extent is attributed to the aggravation of inflammation. However, traditional markers such as C-reactive protein and interleukin-6 show only minor changes during the first year, suggesting that there are other factors involved. The present study evaluates the effect of HD on microinflammation and oxidative stress of uremic patients. Methods We conducted a prospective observational longitudinal study including 30 incident HD patients. Blood samples were collected at baseline and 6 and 12 months. Pro-inflammatory monocytes were quantified using flow cytometry. Proteomic analysis (Olink) was performed on serum. Concentrations of indoxyl sulphate (IS), growth differentiation factor 15 (GDF-15), oxidative status and circulating microRNA (miRNA) expression were also determined. Results A new population of activated monocytes was identified that progressively increased at 1 year of HD. In addition, an increase in the serum concentration of up to 29 inflammation-related proteins was detected, including interleukins, chemokines, tumour necrosis factor family molecules, cell activation molecules and apoptosis-related proteins. Conversely, leukaemia inhibitory factor receptor was downregulated. The concentration of IS was positively correlated with GDF-15 levels. Furthermore, patients exhibited decreased expression of miRNA-126-3p, -130a-3p, -146a-5p, 223-3p, -let7a-5p and -let7b-5p. Conclusion This study highlights the impact of HD on inflammation and oxidative stress, manifested by an increase in activated monocytes and inflammatory markers. The observed subclinical inflammation associated to HD treatment may help in understanding the mechanisms of cardiovascular damage in patients on HD. © 2025 The Author(s). Published by Oxford University Press on behalf of the ERA., We thank all our patients and their families. The study was supported by the European Uremic Toxins Work group (EUTox), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), RICORS2040 (Kidney Disease) (RD21/0005/0008) and COST Action CA21165, Personalized medicine in chronic kidney disease: improved outcome based on Big Data (PerMediK). The authors are grateful to Peralbo Santaella, from the IMIBIC Cytometry Unit, and Cobiomic Bioscience for the technical assistance., This work was support by grants from the National Institute of Health Carlos III (PI17/01785 to A.M.-M. and P22/00883 to F.G. and A.M.-M.), from the Junta de Andalucía (CSyF 2022 project, PI-0130-2022 to F.G. and A.M.-M.) and from Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación MICIU/AEI/10.13039/501100011033 and ‘ERDF/EU’ (PID2022-141034OB-C22 to C.C.-C.). A.C. is supported by a postdoctoral fellowship (ref DOC_01428) from the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities of the Junta de Andalucía, co-financed by the European Union through the European Social Fund ‘The ESF invests in your future’., Peer reviewed